Press Release: Bio-Rad Reports Third-Quarter 2021 Financial Results
Press Release: Bio-Rad Reports Third-Quarter 2021 Financial Results
Bio-Rad Reports Third-Quarter 2021 Financial Results
Bio-Rad報告2021年第三季度財務業績
HERCULES, Calif.--(BUSINESS WIRE)--October 28, 2021--
加利福尼亞州大力神--(美國商業新聞網)--2021年10月28日--
Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader of life science research and clinical diagnostic products, today announced financial results for the third quarter ended September 30, 2021.
生命科學研究和臨牀診斷產品的全球領先企業Bio-Rad實驗室公司(紐約證券交易所市場代碼：BIO和BIOB)今天宣佈了截至2021年9月30日的第三季度財務業績。
Third-quarter 2021 net sales were $747.0 million, an increase of 15.4 percent compared to $647.3 million reported for the third quarter of 2020. On a currency-neutral basis, quarterly sales increased 13.8 percent compared to the same period in 2020. Third-quarter gross margin was 58.6 percent compared to 56.7 percent during the third quarter in 2020.
2021年第三季度淨銷售額為7.47億美元，比2020年第三季度報告的6.473億美元增長15.4%。在匯率中性的基礎上，季度銷售額與2020年同期相比增長了13.8%。第三季度毛利率為58.6%，而2020年第三季度為56.7%。
Life Science segment net sales for the third quarter were $373.5 million, an increase of 15.3 percent compared to the same period in 2020. On a currency-neutral basis, Life Science segment sales increased by 13.9 percent compared to the same quarter in 2020. Currency-neutral sales growth was primarily attributed to sales of our Droplet Digital PCR(R) and Process Media product lines, as well as back royalties from a legal settlement. On a geographic basis, Life Science currency-neutral year-over-year sales grew across the Americas and Asia but declined in Europe. Excluding COVID-19-related sales, European region revenue posted a double-digit percent increase from the year ago period.
生命科學部門第三季度的淨銷售額為3.735億美元，與2020年同期相比增長了15.3%。在匯率中性的基礎上，生命科學部門的銷售額與2020年同期相比增長了13.9%。與貨幣無關的銷售增長主要歸因於我們Droplet Digital PCR(R)和Process Media產品系列的銷售，以及從法律和解中返還的版税。從地理位置來看，生命科學在美洲和亞洲的銷售額同比增長，但在歐洲下降。不包括與新冠肺炎相關的銷售，歐洲地區的收入比去年同期增長了兩位數。
Clinical Diagnostics segment net sales for the third quarter were $372.2 million, an increase of 15.5 percent compared to the same period in 2020. On a currency-neutral basis, net sales increased 13.7 percent versus the same quarter last year. Currency-neutral sales were up for all product lines and across all regions, primarily driven by higher utilization in lab operations as businesses recover from the COVID-19 pandemic.
第三季度臨牀診斷部門的淨銷售額為3.722億美元，比2020年同期增長15.5%。在匯率中性的基礎上，淨銷售額比去年同期增長13.7%。所有產品線和所有地區的貨幣中性銷售額都有所上升，這主要是由於隨着企業從新冠肺炎大流行中恢復，實驗室運營中的利用率更高。
Income from operations during the third quarter of 2021 was $156.8 million versus $109.6 million during the same quarter last year.
2021年第三季度的運營收入為1.568億美元，而去年同期為1.096億美元。
Net income for the third quarter of 2021 was $3,928.0 million, or $129.96 per share on a diluted basis, versus $1,314.8 million, or $43.64 per share on a diluted basis, during the same period in 2020. Net income for the third quarter of 2021 and 2020 was impacted by the recognition of changes in the fair market value of equity securities, primarily related to the holdings of our investment in Sartorius AG. The effective tax rate for the third quarter of 2021 was 21.8 percent, compared to 21.9 percent for the same period in 2020. The tax rates for both periods were driven by the large unrealized gain in equity securities.
2021年第三季度淨收入為39.28億美元，稀釋後每股收益為129.96美元，而2020年同期為13.148億美元，稀釋後每股收益為43.64美元。2021年和2020年第三季度的淨收入受到確認股權證券公允市值變化的影響，這主要與我們在Sartorius AG的投資有關。2021年第三季度的有效税率為21.8%，而2020年同期為21.9%。這兩個時期的税率都是由股權證券的鉅額未實現收益推動的。
"We are pleased with our performance in the third quarter, which reflected strength across many product lines," said Norman Schwartz, Bio-Rad President and Chief Executive Officer. "During the quarter, demand continued for products associated with COVID-19 testing and research, though at a more moderate level," he said.
Bio-Rad總裁兼首席執行官諾曼·施瓦茨(Norman Schwartz)説：“我們對第三季度的表現感到滿意，這反映了許多產品線的實力。”他説：“在本季度，對與新冠肺炎測試和研究相關的產品的需求仍在繼續，儘管處於較温和的水平。”
GAAP Results
------------------------------------------------------------------------------
Q3 2021 Q3 2020
------------------------------------------ ---------------- ----------------
Revenue (millions) $747.0 $647.3
------------------------------------------ ---------------- ----------------
Gross margin 58.6% 56.7%
------------------------------------------ ---------------- ----------------
Operating margin 21.0% 16.9%
------------------------------------------ ---------------- ----------------
Net income (millions) $3,928.0 $1,314.8
------------------------------------------ ---------------- ----------------
Income per diluted share $129.96 $43.64
------------------------------------------ ---------------- ----------------
Non-GAAP Results
------------------------------------------------------------------------------
Q3 2021 Q3 2020
------------------------------------------ ---------------- ----------------
Revenue (millions) $715.2 $647.3
------------------------------------------ ---------------- ----------------
Gross margin 57.9% 57.5%
------------------------------------------ ---------------- ----------------
Operating margin 19.4% 18.8%
------------------------------------------ ---------------- ----------------
Net income (millions) $112.2 $90.3
------------------------------------------ ---------------- ----------------
Income per diluted share $3.71 $3.00
------------------------------------------ ---------------- ----------------
A reconciliation between GAAP operating results and non-GAAP operating results
is provided following the financial statements that are part of this press
release. Non-GAAP adjustments include amortization of purchased intangibles;
acquisition-related expenses and benefits; restructuring, impairment charges
and valuation changes in equity-owned securities; gains and losses on
equity-method investments; significant litigation charges or benefits and
legal costs; and discrete income tax events and the income tax effect on these
non-GAAP adjustments.
GAAP結果------------------------------------------------------------------------------ 2021年第三季度2020第三季度------------------------------------------ ---------------- ---------------- 收入(百萬)747.0美元647.3美元------------------------------------------ ---------------- ---------------- 毛利率58.6%56.7%------------------------------------------ ---------------- ---------------- 營業利潤率21.0%-16.9%------------------------------------------ ---------------- ---------------- 淨收入(百萬)$3,928.0$1,314.8------------------------------------------ ---------------- ---------------- 稀釋後每股收益$129.96$43.64------------------------------------------ ---------------- ---------------- 非GAAP結果------------------------------------------------------------------------------ 2021年第三季度2020第三季度------------------------------------------ ---------------- ---------------- 收入(百萬)715.2美元647.3美元------------------------------------------ ---------------- ---------------- 毛利率57.9%57.5%------------------------------------------ ---------------- ---------------- 營業利潤率19.4%-18.8%------------------------------------------ ---------------- ---------------- 淨收入(百萬)$112.2$90.3------------------------------------------ ---------------- ---------------- 稀釋後每股收益$3.71$3.00------------------------------------------ ---------------- ---------------- GAAP經營業績與非GAAP經營業績之間的對賬是在本刊的財務報表之後提供的放手。非GAAP調整包括購進無形資產的攤銷；與收購相關的費用和福利；重組、減值費用及股權證券的估值變動；權益證券的損益權益法投資；重大訴訟費用或利益以及法律費用；以及離散的所得税事件和所得税對這些事件的影響非GAAP調整。
Non-GAAP net income and non-GAAP diluted income per share (non-GAAP EPS) are non-GAAP measures that exclude certain items detailed later in this press release under the heading "Non-GAAP Reporting."
非GAAP淨收入和非GAAP稀釋每股收益(Non-GAAP EPS)是非GAAP衡量標準，不包括本新聞稿後面“非GAAP報告”標題下詳述的某些項目。
Non-GAAP net income for the third quarter of 2021 was $112.2 million, or $3.71 per share on a diluted basis, compared to $90.3 million, or $3.00 per share on a diluted basis, during the same period in 2020.
2021年第三季度的非GAAP淨收入為1.122億美元，稀釋後每股收益為3.71美元，而2020年同期為9030萬美元，稀釋後每股收益為3.00美元。
The non-GAAP effective tax rate for the third quarter of 2021 was 18.0 percent, compared to 22.5 percent for the same period in 2020. The lower rate in 2021 was driven by the geographic mix of earnings. In addition, the effective tax rate was lower as a result of an increase in compensation related tax deductions.
2021年第三季度的非GAAP有效税率為18.0%，而2020年同期為22.5%。2021年較低的利率是由收入的地理組合推動的。此外，由於與薪酬相關的税收減免增加，實際税率較低。
The following table represents a reconciliation of Bio-Rad's reported net income and diluted income per share to non-GAAP net income and non-GAAP diluted income per share for the three and nine months ended September 30, 2021 and 2020:
下表顯示了截至2021年9月30日和2020年9月30日的3個月和9個月，Bio-Rad公司報告的淨收入和每股攤薄收益與非GAAP淨收入和非GAAP攤薄收益的對賬：
(in thousands,
except per Three Months Ended Nine Months Ended
share data) September 30, September 30,
2021 2020 2021 2020
---------- ---------- ---------- ----------
GAAP net income $ 3,928,033 $ 1,314,824 $ 5,819,561 $ 2,967,165
Legal
settlements (28,083) - (28,619) -
Amortization of
purchased
intangibles 7,097 7,163 21,032 20,257
Legal matters 2,325 5,977 15,501 10,395
Acquisition
related costs
(benefits) - 165 (40) (837)
Restructuring
costs
(benefits) 15 (1,111) 67,799 (827)
Valuation gain
on
equity-owned
securities (4,868,659) (1,580,350) (7,078,753) (3,591,509)
Loss on
equity-method
investments 1,899 183 5,579 2,634
Other
non-recurring
items - - - (11,680)
Income tax
effect on
non-GAAP
adjustments 1,069,577 343,401 1,554,100 800,631
---------- ---------- ---------- ----------
Non-GAAP net
income $ 112,204 $ 90,252 $ 376,160 $ 196,229
========== ========== ========== ==========
GAAP diluted
income per
share $ 129.96 $ 43.64 $ 192.76 $ 98.46
========== ========== ========== ==========
Non-GAAP diluted
income per
share $ 3.71 $ 3.00 $ 12.46 $ 6.51
========== ========== ========== ==========
(以千計，除每三個月至九個月外分享數據)9月30日、9月30日、 2021 2020 2021 2020 ---------- ---------- ---------- ---------- 美國公認會計準則淨收益$3,928,033$1,314,824$5,819,561$2,967,165法律定居點(28,083)-(28,619)-攤銷購得無形資產7,097 7,163 21,032 20,257法律事項2,325 5,977 15,501 10,395採辦相關費用(福利)-165(40)(837)重組費用(福利)15(1,111)67,799(827)估值收益在……上面股權所有證券(4,868,659)(1,580,350)(7,078,753)(3,591,509)虧損發生在權益法投資1,899 183 5,579 2,634其他非重複性項目-(11,680)所得税對…的影響非GAAP調整1,069,577,343,401,554,100 800,631 ---------- ---------- ---------- ---------- 非GAAP淨值收入$112,204$90,252$376,160$196,229 ========== ========== ========== ========== GAAP稀釋每項收入股票$129.96$43.64$192.76$98.46 ========== ========== ========== ========== 非GAAP稀釋每項收入股票$3.71$3.00$12.46$6.51 ========== ========== ========== ==========
On a reported basis, net sales for the first three quarters of 2021 increased 24.7 percent to $2,189.8 million compared to $1,755.8 million for the same period in 2020. On a currency-neutral basis, net sales grew 21.2 percent.
在報告的基礎上，2021年前三個季度的淨銷售額增長了24.7%，達到21.898億美元，而2020年同期為17.558億美元。在匯率中性的基礎上，淨銷售額增長了21.2%。
Year-to-date net income for 2021 was $5,819.6 million, or $192.76 per share on a fully diluted basis, compared to $2,967.2 million, or $98.46 per share during the same period in 2020. The COVID-19 pandemic positively impacted overall results for the first three quarters of the year. On a non-GAAP basis net income for the first three quarters of 2021 was $376.2 million, or $12.46 per share, compared to $196.2 million, or $6.51 per share during the same period in 2020.
今年到目前為止，2021年的淨收入為58.196億美元，或在完全稀釋的基礎上每股192.76美元，而2020年同期為29.672億美元，或每股98.46美元。新冠肺炎疫情對今年前三個季度的整體業績產生了積極影響。在非GAAP的基礎上，2021年前三個季度的淨收入為3.762億美元，或每股12.46美元，而2020年同期為1.962億美元，或每股6.51美元。
"Throughout the year we adapted well to challenges posed by the COVID-19 pandemic, supporting our customers and ensuring the safety of our employees while continuing to make progress on our core strategies," Mr. Schwartz said. "As we head into the end of 2021, we will continue to build on the progress we've made during the first three quarters and expect to generate improved operating profit over 2020," he added.
施瓦茨説，“在這一年裏，我們很好地適應了新冠肺炎疫情帶來的挑戰，支持了我們的客户，確保了員工的安全，同時繼續在我們的核心戰略上取得進展。”他補充説：“在我們邁向2021年底之際，我們將繼續在前三個季度取得進展的基礎上再接再厲，預計2020年營業利潤將有所改善。”
2021 Financial Outlook
2021年財務展望
For the full year 2021, the company has updated its guidance and now anticipates non-GAAP currency-neutral revenue growth between 12 to 13 percent and an estimated non-GAAP operating margin of approximately 19.5 percent. Management will discuss this outlook in greater detail on the third-quarter 2021 financial results conference call.
對於2021年全年，該公司已經更新了其指導方針，現在預計非GAAP貨幣中性的收入增長12%至13%，估計非GAAP營業利潤率約為19.5%。管理層將在2021年第三季度財務業績電話會議上更詳細地討論這一前景。
Use of Non-GAAP Reporting and Currency-Neutral
使用非GAAP報告和貨幣中性
譯文內容由第三人軟體翻譯。